Table I.

Diabetes incidences after LCMV infection and various antibody treatments

TreatmentControlVα14Control + α-GalCerControlCd1d−/−
105 PFU105 PFU105 PFU104 PFU104 PFU
None10/120/121/126/1212/12
Anti-CD2512/1211/12a10/12a12/12aND
Control isotype10/120/121/126/12ND
Anti–TGF-β11/1210/12a10/12a10/12aND
Control isotype10/120/120/127/12ND
120G811/1210/12a10/12a10/12aND
Control isotype10/120/121/126/12ND
Anti-CD62L10/1211/12a10/12aNDND
Control isotype10/121/120/12NDND
  • Incidence of T1D 20 d after LCMV infection with 104 or 105 PFU of Ins-NP mice treated with anti-CD25, anti–TGF-β, 120G8, or anti-CD62L mAbs or with respective control isotype, as indicated. n = 12 for each group of mice.

  • a P-values <0.05 for mAb-treated mice compared with untreated mice.